Market Intelligence, Clinical Progress, and High-Purity Reagents for Epithelial-Mesenchymal Transition (EMT) and Oncology Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CDH1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDH1 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed for native glycosylation. |
View CDH1 Products |
| Gene Delivery | CDH1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and cell-based functional assays. |
View CDH1 Products |
| Benchmark Ab | Anti-CDH1 Recombinant Antibody Recombinant positive control derived from clinical-grade reference sequences. |
View CDH1 Products |
| Validator | CDH1 siRNA Set Target-specific knockdown verification to confirm assay specificity. |
View CDH1 Products |
| Related Target A | CDH2 (N-Cadherin) Key marker for cadherin switching during Epithelial-Mesenchymal Transition (EMT) screening. |
View CDH2 Products |
| Related Target B | CTNNB1 (Beta-catenin) Intracellular binding partner of CDH1; essential for Wnt signaling and cell adhesion pathway analysis. |
View CTNNB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Calcium-Dependent Conformation Loss | ECD-Fc proteins designed with intact EC1-EC5 domains, preserving native calcium-binding pockets. Verified by theoretical MW and SDS-PAGE purity (>95%). |
| Subfamily Cross-Reactivity (e.g., CDH2, CDH4) | High-purity homolog panels available for counter-screening to ensure antibody/small molecule selectivity. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies available as assay positive controls. |
| False Positives in Adhesion Assays | Validated siRNA knockdown sets included to verify target-specific phenotypic rescue. |
Live CDH1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CDH1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and synthetic lethality approaches. CDH1 (E-cadherin) loss is a well-established hallmark of diffuse gastric cancer and lobular breast cancer, making its downstream pathways highly druggable. Concurrently, retaining intact CDH1 expression in specific epithelial tumors has emerged as a target for selective ADC-driven internalization therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting mutant-specific CDH1 conformations and EMT-reversing combination regimens.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | AstraZeneca, Daiichi Sankyo | Gastric Cancer, Breast Cancer | Internalization Assay (Need high-purity ECD-Fc to validate antibody binding and receptor-mediated endocytosis) |
| Bispecific / Multispecific | Amgen, Roche | Solid Tumors | Heterodimer Validation (Need cross-reactive antigens and stable cell lines expressing native CDH1) |
| Small Molecule / PROTAC | Pfizer, Academic Consortia | HDGC (Hereditary Diffuse Gastric Cancer) | Selectivity Assay (Need mutant vs WT proteins to identify selective binders or degraders) |